Abstract
CD26 is a surface glycoprotein with intrinsic dipeptidyl peptidase IV (DPPIV) enzyme activity with multiple biological roles, including being intricately involved in immunoregulation as a T-cell activation molecule and as a regulator of chemokine function. T-cell lymphoid malignancies represent a heterogeneous group of diseases that are generally aggressive and are for the most part resistant to current treatment modalities. Previous studies showed that CD26 is expressed on selected T-cell neoplasms, suggesting a potential role for CD26 in tumor development. We review herein recent classification schemes for T-cell lymphoid malignancies that take into account various facets of their clinical presentation. In addition, we discuss findings supporting the conclusion that CD26 has an essential role in human T-cell activation, as well as its ability to regulate the biological effects of selected chemokines through its DPPIV activity. Finally, we will present recent work from our laboratory that indicates a potential role for CD26 as a molecular target for novel treatment modalities for T-cell lymphoid malignancies.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adenosine Deaminase Inhibitors
-
Amino Acid Sequence
-
Animals
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use
-
Antigens, Neoplasm / drug effects
-
Antigens, Neoplasm / physiology*
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use
-
Cell Cycle / drug effects
-
Cell Cycle / physiology
-
Clinical Trials as Topic
-
Dipeptidyl Peptidase 4 / drug effects
-
Dipeptidyl Peptidase 4 / physiology*
-
Doxorubicin / pharmacology
-
Drug Design
-
Enzyme Inhibitors / pharmacology
-
Enzyme Inhibitors / therapeutic use
-
Humans
-
Jurkat Cells / enzymology
-
Leukemia, T-Cell / classification
-
Leukemia, T-Cell / drug therapy*
-
Leukemia, T-Cell / enzymology
-
Lymphocyte Activation / physiology*
-
Lymphocyte Cooperation / physiology*
-
Lymphoma, T-Cell / classification
-
Lymphoma, T-Cell / drug therapy*
-
Lymphoma, T-Cell / enzymology
-
Lymphoproliferative Disorders / drug therapy
-
Lymphoproliferative Disorders / enzymology
-
Mice
-
Mice, SCID
-
Molecular Sequence Data
-
Neoplasm Proteins / antagonists & inhibitors
-
Pentostatin / pharmacology
-
Pentostatin / therapeutic use
-
Prognosis
-
Transfection
-
World Health Organization
Substances
-
Adenosine Deaminase Inhibitors
-
Antibodies, Monoclonal
-
Antigens, Neoplasm
-
Antineoplastic Agents
-
Enzyme Inhibitors
-
Neoplasm Proteins
-
Pentostatin
-
Doxorubicin
-
Dipeptidyl Peptidase 4